1.

Correction to: Public Policy in ALS/MND Care: The Belgian Perspective

1.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

2.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

3.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

4.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

5.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

6.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

7.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

8.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

9.

Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR)

1.

Specialized multidisciplinary care improves ALS survival in Belgium: a population-based retrospective study

1.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

2.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

3.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

4.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

5.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

6.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

7.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.

1.

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen

2.

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen

3.

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen

4.

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen

5.

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen

1.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

2.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

3.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

4.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

5.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

6.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

7.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

8.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

9.

Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

1.

Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

2.

Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

3.

Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

1.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

2.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

3.

NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

1.

Capturing the fusion of two ancestries and kinship structures in Merovingian Flanders

1.

Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort